This content is machine translated Swiss Society of Cardiology Joint Annual Meeting 2018, Basel Advances in atherosclerosis therapy The PCSK9 inhibitors evolocumab and alirocumab can be used successfully to lower LDL cholesterol, as shown by large outcome studies. Whether anti-inflammation can also prophylactically reduce cardiovascular risk has been…
